Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on January 21, 2014, with the latest event reported on January 27, 2014. The filing primarily addresses modifications to executive compensation and the issuance of international patents for the company's ADHD product candidate, SPN-812.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on non-financial operational events and executive compensation adjustments rather than financial performance metrics.
Material Changes and Executive Compensation
The Compensation Committee approved modifications to the compensation of six executive officers, effective January 1, 2014. The changes include base salary increases, 2013 performance bonuses, and new stock option grants:
- Jack A. Khattar (CEO): Base salary increased to $486,675; awarded $231,750 bonus; granted 150,000 options at $9.56/share.
- Gregory S. Patrick (CFO): Base salary increased to $318,270; awarded $109,020 bonus; granted 50,000 options at $9.24/share.
- Stefan K.F. Schwabe (CMO): Base salary increased to $342,860; awarded $111,850 bonus; granted 40,000 options at $9.24/share; 2014 bonus target increased to 40% of base salary.
- Padmanabh P. Bhatt (CSO): Base salary increased to $324,635; awarded $90,770 bonus; granted 30,000 options at $9.24/share.
- Jones W. Bryan (VP Business Development): Base salary increased to $265,225; awarded $72,620 bonus; granted 30,000 options at $9.24/share.
- Victor L. Vaughn (SVP Sales): Base salary increased to $283,250; awarded $74,250 bonus; granted 30,000 options at $9.24/share.
All stock options vest annually in equal increments over a four-year period.
Outlook, Risks, and Other Events
On January 27, 2014, the company announced the issuance of European and Canadian patents for SPN-812, a novel non-stimulant product candidate for the treatment of ADHD. These patents provide protection with an expiration date no earlier than 2029. Additional patent applications for SPN-812 are pending in other regions, including the United States. The filing does not contain specific management commentary on financial outlook or new risk factors beyond the standard patent protection context.
Investor Verification Checklist
- Verify the total dilution impact of the 330,000 new stock options granted to executives.
- Confirm the status of pending U.S. patent applications for SPN-812 to assess full global protection.
- Review the company's cash burn rate to ensure sufficient liquidity to fund the increased executive compensation and ongoing R&D for SPN-812.
- Check subsequent filings for the commercialization timeline of SPN-812 following the patent grants.